Wellington woman Amanda Broughton will have to pay $103,000 for a course of a drug, to treat her stage 3C breast cancer. The ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

The agency approved a perioperative Keytruda regimen based on a 30 percent reduction in the risk of recurrence, progression, or death versus the control arm.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Merck also introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head ...

The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express ...